Davis Polk advised the underwriters in connection with the SEC-registered offering of 5,750,000 shares of common stock of Stemline Therapeutics, Inc. for total gross proceeds of approximately $88 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “STML.”
Stemline is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics.
The Davis Polk capital markets team included partners Richard D. Truesdell Jr. and Derek Dostal and associates Jacqueline Marino, Roman Shapurko and Concepción Olivera. Counsel Bonnie Chen and associate Yifu Chen provided intellectual property and technology advice. Partner William A. Curran provided tax advice. All members of the Davis Polk team are based in the New York office.